HIV injection that provides two months of continuous protection against HIV infection has been approved

• The injectable form can provide two months of continuous protection against HIV virus 
• Herve Verhoosel  says a year’s supply in the United States costs $20,000(ksh2.3 million). 

Global health agencies have revealed that a voluntary licensing agreement has been reached to allow for the generic production of the first and only long-acting injectable HIV-prevention drug for Sub-Saharan Africa.

Initially, the HIV-prevention known as Cabotegravir, was available only in pill form and had to be taken daily, or in some cases before and after sex. 

After months of research and lab tests it’s a sigh of relief for S3x maniac especially those who love it raw since the injectable form can provide two months of continuous protection against HIV infection through a single intramuscular injection.

However, the UNITAID, Spokesperson Herve Verhoosel  says a year’s supply in the United States costs $20,000(ksh2.3 million). 

Herve Verhoosel Also added that due to its high price, the license will give three different generic manufacturers to develop the product on a generic base.

He notes it might take two or more years to develop the generic product. He says the price, which is not yet known, will likely be determined then.

He also added that cabotegravir will be available to people at high risk in the least developed, low-income, lower-middle income, and sub-Saharan African countries. He says people with high rates of infection will benefit most from this medication. They include men who have sex with men, sex workers, transgender women, adolescent girls, and young women.